COMPLEMENTARY DIAGNOSIS
COMPANION DIAGNOSIS
Complementary Diagnostic Kits for Oncomatryx precision drugs _
Oncomatryx is developing Complementary Diagnostic kits to select and monitor patients to be treated with our precision stromal targeted drugs.
These devices, based on immunohistochemistry (IHC) and ELISA, allow the detection of Oncomatryx's therapeutic target proteins, FAPα and ENG, in tumor biopsies and blood samples. For these developments, Oncomatryx has generated its own monoclonal antibodies that specifically detect target proteins in human samples. COMPANY
These tools will guide the selection, stratification and subsequent monitoring of patients who can be treated with Oncomatryx ADCs.
Oncomatryx has also developed and validated primers and protocols for Q-PCR, which allow determining the gene expression of human and mouse FAPα in samples of tumor-associated stroma.
In addition to the systems for determining FAPα at the level of mRNA and protein in tissue and blood, Oncomatryx is carrying out comparative genomic and proteomic studies between preclinical pancreatic cancer models of xenotransplanted mice with tumors derived from patients who presented different levels of response to drug treatment, to identify new patient selection biomarkers for the administration of ADCs, as well as subsequent monitoring of treated patients.
Oncomatryx is also developing companion diagnostic tools based on COL11A1. Two ELISA and RT-PCR systems are undergoing validation for the detection of COL11A1 in serum and plasma samples. These tools will guide the selection of the most appropriate treatment for patients with tumors of different types, will help monitor the efficacy of treatments, and will facilitate early detection of recurrences.
